Sale!

Immunohistochemistry PDL1 SP142 Test

Original price was: 3,000 د.إ.Current price is: 2,700 د.إ.

-10%

The Immunohistochemistry PDL1 SP142 Test is a specialized diagnostic procedure performed to evaluate the expression of the Programmed Death-Ligand 1 (PD-L1) protein in cancer cells. This test is particularly significant in the context of certain cancers, such as non-small cell lung cancer (NSCLC), as it helps in determining the suitability of patients for immunotherapy treatments targeting the PD-1/PD-L1 pathway. The SP142 clone is utilized in this assay to specifically detect PD-L1 expression, which can be pivotal in guiding therapeutic decisions and predicting patient response to specific immunotherapies.

At DNA Labs UAE, this test is offered at a cost of 2700 AED. The laboratory is equipped with advanced technologies and staffed by experienced professionals to ensure accurate and reliable results. Conducting the Immunohistochemistry PDL1 SP142 Test at DNA Labs UAE involves a meticulous process of preparing and analyzing tissue samples, with results that can significantly impact treatment planning and outcomes for patients with certain types of cancer.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

IMMUNOHISTOCHEMISTRY PDL1 SP142 Test

Test Cost: AED 2700.0

Components:

  • Price: 2700.0 AED

Sample Condition:

Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.

Report Delivery:

  • Sample: Daily by 6 pm
  • Report Block: 5 days
  • Tissue Biopsy: 5 days
  • Tissue large complex: 7 days

Method:

Immunohistochemistry

Test Type:

Cancer

Doctor:

Oncologist

Test Department:

HISTOLOGY

Pre Test Information:

Test Details: The PD-L1 SP142 test is an immunohistochemistry assay used to detect the expression of programmed death-ligand 1 (PD-L1) in tumor tissues. PD-L1 is a protein that is expressed on the surface of cancer cells and can inhibit the immune response against the tumor. The SP142 test involves staining tumor tissue sections with a specific antibody against PD-L1. This antibody binds to PD-L1 protein if it is present on the tumor cells. The stained tissue sections are then examined under a microscope to determine the level of PD-L1 expression. The PD-L1 SP142 test is commonly used in clinical practice to guide treatment decisions for patients with certain types of cancer, such as non-small cell lung cancer and urothelial carcinoma. The test results can help identify patients who may benefit from treatment with immune checkpoint inhibitors, which are drugs that block the interaction between PD-L1 and its receptor on immune cells, allowing the immune system to attack the tumor. It is important to note that the PD-L1 SP142 test is just one of several assays available to assess PD-L1 expression. Different tests may use different antibodies and have different scoring systems, which can impact the interpretation of the results. Therefore, it is essential to follow the specific guidelines and recommendations provided by the test manufacturer and/or clinical guidelines when using the PD-L1 SP142 test in clinical practice.

Test Name IMMUNOHISTOCHEMISTRY PDL1 SP142 Test
Components
Price 2700.0 AED
Sample Condition Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Report Delivery Sample Daily by 6 pm; Report Block: 5 daysTissue Biopsy: 5 days Tissue large complex : 7 days
Method Immunohistochemistry
Test type Cancer
Doctor Oncologist
Test Department: HISTOLOGY
Pre Test Information
Test Details

The PD-L1 SP142 test is an immunohistochemistry assay used to detect the expression of programmed death-ligand 1 (PD-L1) in tumor tissues. PD-L1 is a protein that is expressed on the surface of cancer cells and can inhibit the immune response against the tumor.

The SP142 test involves staining tumor tissue sections with a specific antibody against PD-L1. This antibody binds to PD-L1 protein if it is present on the tumor cells. The stained tissue sections are then examined under a microscope to determine the level of PD-L1 expression.

The PD-L1 SP142 test is commonly used in clinical practice to guide treatment decisions for patients with certain types of cancer, such as non-small cell lung cancer and urothelial carcinoma. The test results can help identify patients who may benefit from treatment with immune checkpoint inhibitors, which are drugs that block the interaction between PD-L1 and its receptor on immune cells, allowing the immune system to attack the tumor.

It is important to note that the PD-L1 SP142 test is just one of several assays available to assess PD-L1 expression. Different tests may use different antibodies and have different scoring systems, which can impact the interpretation of the results. Therefore, it is essential to follow the specific guidelines and recommendations provided by the test manufacturer and/or clinical guidelines when using the PD-L1 SP142 test in clinical practice.